A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada

Auteurs-es

  • Nimira S. Alimohamed University of Calgary
  • Geoffrey Gotto University of Calgary
  • Girish S. Kulkarni University of Toronto
  • Peter C. Black University of British Columbia
  • Wassim Kassouf McGill University
  • Srikala S. Sridhar University of Toronto
  • Andrea Kokorovic Dalhousie University
  • Bernhard J. Eigl BC Cancer
  • Normand Blais Universite de Montreal
  • Aly-Khan A. Lalani McMaster University
  • Winson Y. Cheung University of Calgary
  • Mariet Stephen Oncology Outcomes, Calgary
  • Brendan J.W. Osborne Johnson & Johnson Innovative Medicine
  • Christopher J.D. Wallis University of Toronto

DOI :

https://doi.org/10.5489/cuaj.9111

Mots-clés :

Muscle invasive bladder cancer, Outcomes, Survival, Treatment, Chemotherapy, Cystectomy, Radiation therapy

Résumé

INTRODUCTION: Approximately 25% of patients diagnosed with bladder cancer have muscle-invasive disease (MIBC). While real-world data have highlighted opportunities to improve curative-intent treatment rates, comprehensive population-level data in Canada are limited. This study aimed to assess patterns of care and outcomes in a real-world cohort of MIBC in Canada.

METHODS: This retrospective, observational study describes baseline characteristics, treatment patterns, and overall survival (OS) of individuals with de novo MIBC diagnosed between 2010 and 2020 in Alberta, Canada. Data from adult patients with MIBC (T2-T4, N0/1, M0) were obtained from administrative databases and analyzed using basic statistics, multivariate regression analyses, and the Kaplan-Meier method.

RESULTS: We identified 1292 patients with de novo MIBC. Of these, 76% were male with a median age of 73 years, 68% had cT2, and 76% had cN0 disease; approximately half had a Charlson comorbidity index (CCI) ≥1. Overall, 25% did not receive active treatment, while 58% received curative-intent treatment (49% underwent radical cystectomy [RC] and 9% received chemoradiotherapy), and 17% received some form of non-curative-intent treatment. Of those who underwent RC, 45% received neoadjuvant chemotherapy (NAC). Median overall survival (mOS) in the entire cohort was 2.1 years (95% confidence interval 1.9-2.4). Key predictors of inferior survival were age ≥76 years, CCI score of ≥1, T4 tumor stage, or not receiving NAC.

CONCLUSIONS: This real-world analysis highlights opportunities to improve outcomes for patients with MIBC. Increasing access to curative-intent treatments, particularly in the elderly and those with comorbidities, is likely to enhance patient care and outcomes.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Bibliographies de l'auteur-e

Nimira S. Alimohamed, University of Calgary

Department of Medicine, Division of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.

1331 29 Street NW, Calgary, AB T2N 4N2

(403) 521-3723

Geoffrey Gotto, University of Calgary

Clinical Associate Professor, Departments of Surgery and Oncology, The University of Calgary, Calgary, Alberta, Canada.

Medical Director, Clinic for Advanced and Metastatic Prostate Cancer (CAMP), Prostate Cancer Centre, Calgary, Alberta, Canada.

Urologic Oncologist, Southern Alberta Institute of Urology, Calgary, Alberta, Canada.

Girish S. Kulkarni, University of Toronto

Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Peter C. Black, University of British Columbia

Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

 

Wassim Kassouf, McGill University

Department of Surgery (Urology), McGill University Health Center, Montreal, Quebec, Canada.

Srikala S. Sridhar, University of Toronto

Division of Medical Oncology, University of Toronto, Princess Margaret Cancer Centre,  Toronto, Ontario, Canada.

Andrea Kokorovic, Dalhousie University

Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada

Bernhard J. Eigl, BC Cancer

BC Cancer, Vancouver, British Columbia, Canada.

Normand Blais, Universite de Montreal

Division of Medical Oncology and Hematology, Department of Medicine, Centre Hospitalier de l'Université de Montréal; Université de Montréal, Montreal, Quebec, Canada.

Aly-Khan A. Lalani, McMaster University

Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.

Christopher J.D. Wallis, University of Toronto

Urologic Oncology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Publié-e

2025-08-28

Comment citer

Alimohamed, N. S., Gotto, G., Kulkarni, G. S., Black, P. C., Kassouf, W., Sridhar, S. S., … Wallis, C. J. (2025). A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada. Canadian Urological Association Journal, 19(12), 393–402. https://doi.org/10.5489/cuaj.9111

Numéro

Rubrique

Original Research